{"id": "article-37354_0", "title": "Transcatheter Aortic Valve Replacement -- Continuing Education Activity", "content": "Surgical aortic valve replacement has been the standard treatment for patients with severe symptomatic aortic stenosis (AS). Previously, patients determined to be at high risk for surgery could only be offered diuretics and balloon valvuloplasty which served as palliative treatment and had no effect on long-term outcomes. The development of transcatheter aortic valve replacement (TAVR) has emerged as a lifeline for patients considered to be inoperable providing both an improvement in symptoms and statistically significant mortality benefit. This activity reviews the evaluation and treatment of aortic valves using TAVR and discusses the role of the interprofessional team in evaluating and treating this condition.", "contents": "Transcatheter Aortic Valve Replacement -- Continuing Education Activity. Surgical aortic valve replacement has been the standard treatment for patients with severe symptomatic aortic stenosis (AS). Previously, patients determined to be at high risk for surgery could only be offered diuretics and balloon valvuloplasty which served as palliative treatment and had no effect on long-term outcomes. The development of transcatheter aortic valve replacement (TAVR) has emerged as a lifeline for patients considered to be inoperable providing both an improvement in symptoms and statistically significant mortality benefit. This activity reviews the evaluation and treatment of aortic valves using TAVR and discusses the role of the interprofessional team in evaluating and treating this condition."}
{"id": "article-37354_1", "title": "Transcatheter Aortic Valve Replacement -- Continuing Education Activity", "content": "Objectives: Identify the anatomical structures involved in transcatheter aortic valve replacement. Describe the technique involved in performing transcatheter aortic valve replacement. Outline the potential complications of transcatheter aortic valve replacement. Summarize interprofessional team strategies for enhancing care coordination and communication to advance patients outcomes using transcatheter aortic valve replacement. Access free multiple choice questions on this topic.", "contents": "Transcatheter Aortic Valve Replacement -- Continuing Education Activity. Objectives: Identify the anatomical structures involved in transcatheter aortic valve replacement. Describe the technique involved in performing transcatheter aortic valve replacement. Outline the potential complications of transcatheter aortic valve replacement. Summarize interprofessional team strategies for enhancing care coordination and communication to advance patients outcomes using transcatheter aortic valve replacement. Access free multiple choice questions on this topic."}
{"id": "article-37354_2", "title": "Transcatheter Aortic Valve Replacement -- Introduction", "content": "Aortic stenosis (AS) is caused by progressive calficiation of the valve and is the most common cause of left ventricular outflow tract obstruction.\u00a0 Once moderate AS is present, there is a high liklihood of progression to severe AS.\u00a0 Surgical aortic valve replacement has been the standard treatment for patients with severe symptomatic AS. Previously, patients determined to be at high risk for surgery could only be offered diuretics and balloon valvuloplasty which served as palliative treatment and had no effect on long-term outcomes. The development of transcatheter aortic valve replacement (TAVR) has emerged as a lifeline for patients considered to be inoperable providing both improvement in symptoms and statistically significant mortality benefit. [1] [2] [3]", "contents": "Transcatheter Aortic Valve Replacement -- Introduction. Aortic stenosis (AS) is caused by progressive calficiation of the valve and is the most common cause of left ventricular outflow tract obstruction.\u00a0 Once moderate AS is present, there is a high liklihood of progression to severe AS.\u00a0 Surgical aortic valve replacement has been the standard treatment for patients with severe symptomatic AS. Previously, patients determined to be at high risk for surgery could only be offered diuretics and balloon valvuloplasty which served as palliative treatment and had no effect on long-term outcomes. The development of transcatheter aortic valve replacement (TAVR) has emerged as a lifeline for patients considered to be inoperable providing both improvement in symptoms and statistically significant mortality benefit. [1] [2] [3]"}
{"id": "article-37354_3", "title": "Transcatheter Aortic Valve Replacement -- Introduction", "content": "The concept of transcatheter balloon expandable valves was first introduced in the 1980s by a Danish researcher by the name of H. R. Anderson who began testing this idea on pigs. In 2002, Dr. Alain Cribier performed the first successful percutaneous aortic valve replacement on an inoperable patient. The first approval of TAVR for the indication of severe AS in prohibitive risk patients came in\u00a02011. In 2012, the FDA approved TAVR in patients at high surgical risk. In 2015 the indication was expanded to include \u201cvalve-in-valve\u201d procedure for failed surgical bioprosthetic valves. In 2016 the FDA approved\u00a0TAVR valves for use in\u00a0patients with severe AS at intermediate risk.\u00a0\u00a0Following the results of the PARTNER-3 trial published in 2019, the FDA further expanded the indication for TAVR valves to include low risk patients.", "contents": "Transcatheter Aortic Valve Replacement -- Introduction. The concept of transcatheter balloon expandable valves was first introduced in the 1980s by a Danish researcher by the name of H. R. Anderson who began testing this idea on pigs. In 2002, Dr. Alain Cribier performed the first successful percutaneous aortic valve replacement on an inoperable patient. The first approval of TAVR for the indication of severe AS in prohibitive risk patients came in\u00a02011. In 2012, the FDA approved TAVR in patients at high surgical risk. In 2015 the indication was expanded to include \u201cvalve-in-valve\u201d procedure for failed surgical bioprosthetic valves. In 2016 the FDA approved\u00a0TAVR valves for use in\u00a0patients with severe AS at intermediate risk.\u00a0\u00a0Following the results of the PARTNER-3 trial published in 2019, the FDA further expanded the indication for TAVR valves to include low risk patients."}
{"id": "article-37354_4", "title": "Transcatheter Aortic Valve Replacement -- Anatomy and Physiology", "content": "The normal aortic valve is one of two semilunar valves and separates the left ventricle from the aorta.\u00a0 It is comprised of three leaflets/cusps\u00a0(left coronary, right coronary and non-coronary cusp) that are attached to an aortic annulus normally opening to approximately 3-5 cm\u00b2.\u00a0 Transthoracic echocardiography is typically used to evaluate the aortic valve, however additional imaging modalities including transesophageal echocardiography and CT are also commonly used. An aortic valve is considered severely stenotic when it opens to an area of \u22641.0 cm\u00b2. High gradient AS is the most common form of severe AS and is defined by the mean gradient of \u226540 mmHg and an aortic jet velocity of >4 m/s across the valve.\u00a0Low flow, low gradient severe AS is a less common form of severe AS. This subset of patients has low flow rate across the valve either due to systolic dysfunction with reduced ejection fraction or small ventricular volumes secondary to left ventricular hypertrophy (with normal LVEF). When LVEF is normal, low flow is defined as a stroke volume index =35 mL/m\u00b2. Patients with low flow and depressed LVEF undergo dobutamine stress echocardiogram to differentiate true severe stenosis from pseudostenosis (inadequate valve cusp opening caused by low cardiac output causing an artefactually low value).", "contents": "Transcatheter Aortic Valve Replacement -- Anatomy and Physiology. The normal aortic valve is one of two semilunar valves and separates the left ventricle from the aorta.\u00a0 It is comprised of three leaflets/cusps\u00a0(left coronary, right coronary and non-coronary cusp) that are attached to an aortic annulus normally opening to approximately 3-5 cm\u00b2.\u00a0 Transthoracic echocardiography is typically used to evaluate the aortic valve, however additional imaging modalities including transesophageal echocardiography and CT are also commonly used. An aortic valve is considered severely stenotic when it opens to an area of \u22641.0 cm\u00b2. High gradient AS is the most common form of severe AS and is defined by the mean gradient of \u226540 mmHg and an aortic jet velocity of >4 m/s across the valve.\u00a0Low flow, low gradient severe AS is a less common form of severe AS. This subset of patients has low flow rate across the valve either due to systolic dysfunction with reduced ejection fraction or small ventricular volumes secondary to left ventricular hypertrophy (with normal LVEF). When LVEF is normal, low flow is defined as a stroke volume index =35 mL/m\u00b2. Patients with low flow and depressed LVEF undergo dobutamine stress echocardiogram to differentiate true severe stenosis from pseudostenosis (inadequate valve cusp opening caused by low cardiac output causing an artefactually low value)."}
{"id": "article-37354_5", "title": "Transcatheter Aortic Valve Replacement -- Indications", "content": "Indications for aortic valve replacement (surgical or transcatheter) are\u00a0as follows: Severe high-gradient AS with symptoms (class I recommendation, level B evidence) Asymptomatic patients with severe AS and LVEF < 50 (class I recommendation, level B evidence) Severe AS when undergoing other cardiac surgery (class I recommendation, level B evidence) Asymptomatic severe AS and low surgical risk (class IIa recommendation, level B evidence) Symptomatic with low-flow/low-gradient severe AS (class IIa recommendation, level B evidence) Moderate AS and undergoing other cardiac surgery (class IIa recommendation, level C evidence) TAVR is approved for\u00a0the following: Low\u00a0to prohibitive surgical risk patients with severe AS Valve-in-valve procedures for failed prior bioprosthetic valves", "contents": "Transcatheter Aortic Valve Replacement -- Indications. Indications for aortic valve replacement (surgical or transcatheter) are\u00a0as follows: Severe high-gradient AS with symptoms (class I recommendation, level B evidence) Asymptomatic patients with severe AS and LVEF < 50 (class I recommendation, level B evidence) Severe AS when undergoing other cardiac surgery (class I recommendation, level B evidence) Asymptomatic severe AS and low surgical risk (class IIa recommendation, level B evidence) Symptomatic with low-flow/low-gradient severe AS (class IIa recommendation, level B evidence) Moderate AS and undergoing other cardiac surgery (class IIa recommendation, level C evidence) TAVR is approved for\u00a0the following: Low\u00a0to prohibitive surgical risk patients with severe AS Valve-in-valve procedures for failed prior bioprosthetic valves"}
{"id": "article-37354_6", "title": "Transcatheter Aortic Valve Replacement -- Contraindications", "content": "Life expectancy less than 12 months owing to a noncardiac cause, myocardial infarction within the last thirty days, congenital unicuspid, bicuspid or noncalcified valve, hypertrophic cardiomyopathy, short distance between the annulus and coronary ostium, need for emergency surgery, left ventricular ejection fraction less than 20%, severe pulmonary hypertension with right ventricular dysfunction, echocardiographic evidence of intracardiac mass, thrombus or vegetation, native aortic annulus smaller than 18 or larger than 25 mm, severe mitral regurgitation, MRI confirmed CVA or TIA within last six months, end-stage renal disease, mixed aortic valve disease (concomitant aortic regurgitation), or significant aortic disease. [4]", "contents": "Transcatheter Aortic Valve Replacement -- Contraindications. Life expectancy less than 12 months owing to a noncardiac cause, myocardial infarction within the last thirty days, congenital unicuspid, bicuspid or noncalcified valve, hypertrophic cardiomyopathy, short distance between the annulus and coronary ostium, need for emergency surgery, left ventricular ejection fraction less than 20%, severe pulmonary hypertension with right ventricular dysfunction, echocardiographic evidence of intracardiac mass, thrombus or vegetation, native aortic annulus smaller than 18 or larger than 25 mm, severe mitral regurgitation, MRI confirmed CVA or TIA within last six months, end-stage renal disease, mixed aortic valve disease (concomitant aortic regurgitation), or significant aortic disease. [4]"}
{"id": "article-37354_7", "title": "Transcatheter Aortic Valve Replacement -- Personnel", "content": "A multidisciplinary team is needed for the TAVR procedure as well as follow up care.\u00a0 The procedural team typically consists of an interventional cardiologist specially trained in TAVR, a cardiac surgeon, an echocardiographic imaging specialist, skilled nurses and a cardiac anesthesiologist if more than conscious sedation is to be administered.\u00a0\u00a0Cardiac electrophysiologists, neurologists, nephrologists and vascular surgeons must be readily available if complications from the procedure arise.", "contents": "Transcatheter Aortic Valve Replacement -- Personnel. A multidisciplinary team is needed for the TAVR procedure as well as follow up care.\u00a0 The procedural team typically consists of an interventional cardiologist specially trained in TAVR, a cardiac surgeon, an echocardiographic imaging specialist, skilled nurses and a cardiac anesthesiologist if more than conscious sedation is to be administered.\u00a0\u00a0Cardiac electrophysiologists, neurologists, nephrologists and vascular surgeons must be readily available if complications from the procedure arise."}
{"id": "article-37354_8", "title": "Transcatheter Aortic Valve Replacement -- Preparation", "content": "An interprofessional heart team evaluates patients and puts them through extensive evaluation and pre-procedural testing to determine candidacy before undergoing a TAVR. The heart team consists of cardiologists, cardiothoracic surgeons and anesthesiologists. In addition to transthoracic echocardiography, transesophageal echocardiography is often utilized for better visualization of aortic valve anatomy. Computed tomography\u00a0angiography (CTA) of the chest, abdomen, and pelvis are also performed for accurate measurement of the aortic annulus for determination of valve size. CTA\u00a0is also essential for visualization of the vascular anatomy and determination of the approach to be taken. Left heart catheterization is commonly done\u00a0prior to TAVR to provide invasive hemodynamic measurements as well as rule out any coexisting cornary artery disease (CAD) that may be contributing to symptoms or may need revascularization before determination of either surgical or transcatheter approach. Factors that may influence the decision to pursue surgical aortic valve replacement include the need for concomitant coronary artery bypass grafting. Revascularization of stable CAD prior/during TAVR was previously a subject of debate, however\u00a0data published in 2019 showed revascularization in conjunction with TAVR\u00a0failed to offer additional clinical advantage and did not improve important clinical outcomes (risk of MI, stroke or death at 30 days). [5]", "contents": "Transcatheter Aortic Valve Replacement -- Preparation. An interprofessional heart team evaluates patients and puts them through extensive evaluation and pre-procedural testing to determine candidacy before undergoing a TAVR. The heart team consists of cardiologists, cardiothoracic surgeons and anesthesiologists. In addition to transthoracic echocardiography, transesophageal echocardiography is often utilized for better visualization of aortic valve anatomy. Computed tomography\u00a0angiography (CTA) of the chest, abdomen, and pelvis are also performed for accurate measurement of the aortic annulus for determination of valve size. CTA\u00a0is also essential for visualization of the vascular anatomy and determination of the approach to be taken. Left heart catheterization is commonly done\u00a0prior to TAVR to provide invasive hemodynamic measurements as well as rule out any coexisting cornary artery disease (CAD) that may be contributing to symptoms or may need revascularization before determination of either surgical or transcatheter approach. Factors that may influence the decision to pursue surgical aortic valve replacement include the need for concomitant coronary artery bypass grafting. Revascularization of stable CAD prior/during TAVR was previously a subject of debate, however\u00a0data published in 2019 showed revascularization in conjunction with TAVR\u00a0failed to offer additional clinical advantage and did not improve important clinical outcomes (risk of MI, stroke or death at 30 days). [5]"}
{"id": "article-37354_9", "title": "Transcatheter Aortic Valve Replacement -- Technique or Treatment", "content": "Multiple transcatheter aortic valves are available on the market. However, the only two currently\u00a0FDA-approved for use in\u00a0the United States are the SAPIEN valves (Edwards Lifesciences, Irvine, CA) and the CORE valves (Medtronic Fridley, MN). The SAPIEN valves are composed of bovine pericardial tissue and a chromium cobalt alloy frame. The SAPIEN valves are balloon expandable. The newest generation Medtronic valve is the EVOLUT-R. It is composed of porcine tissue and a nitinol frame. This valve has the advantage of being self-expandable (not requiring balloon expansion) and has the ability for repositioning after deployment. To date, there have not been any head-to-head trials comparing these two TAVR valves. [6] [7] [8]", "contents": "Transcatheter Aortic Valve Replacement -- Technique or Treatment. Multiple transcatheter aortic valves are available on the market. However, the only two currently\u00a0FDA-approved for use in\u00a0the United States are the SAPIEN valves (Edwards Lifesciences, Irvine, CA) and the CORE valves (Medtronic Fridley, MN). The SAPIEN valves are composed of bovine pericardial tissue and a chromium cobalt alloy frame. The SAPIEN valves are balloon expandable. The newest generation Medtronic valve is the EVOLUT-R. It is composed of porcine tissue and a nitinol frame. This valve has the advantage of being self-expandable (not requiring balloon expansion) and has the ability for repositioning after deployment. To date, there have not been any head-to-head trials comparing these two TAVR valves. [6] [7] [8]"}
{"id": "article-37354_10", "title": "Transcatheter Aortic Valve Replacement -- Technique or Treatment", "content": "The procedure is typically done in a hybrid room with both operating room and cath lab capabilities. The team consists of interventional cardiologist, cardiac surgeon, and anesthesiologist. The procedure is done under direct visualization with fluoroscopy and occasionally transesophageal\u00a0echocardiogram (TEE) guidance. The most preferred and least invasive approach is the transfemoral approach. If not feasible, an alternate an often more invasive method may need to be used (subclavian, apical, trans-aortic).", "contents": "Transcatheter Aortic Valve Replacement -- Technique or Treatment. The procedure is typically done in a hybrid room with both operating room and cath lab capabilities. The team consists of interventional cardiologist, cardiac surgeon, and anesthesiologist. The procedure is done under direct visualization with fluoroscopy and occasionally transesophageal\u00a0echocardiogram (TEE) guidance. The most preferred and least invasive approach is the transfemoral approach. If not feasible, an alternate an often more invasive method may need to be used (subclavian, apical, trans-aortic)."}
{"id": "article-37354_11", "title": "Transcatheter Aortic Valve Replacement -- Complications", "content": "Possible complications to TAVR include conduction disturbances and the need for a permanent pacemaker, stroke, paravalvular leak, vascular site complications, bleeding, annular rupture, left ventricular perforation, cardiac tamponade, need for surgery, acute myocardial infarction, acute kidney injury, infection, hypotension, and death.", "contents": "Transcatheter Aortic Valve Replacement -- Complications. Possible complications to TAVR include conduction disturbances and the need for a permanent pacemaker, stroke, paravalvular leak, vascular site complications, bleeding, annular rupture, left ventricular perforation, cardiac tamponade, need for surgery, acute myocardial infarction, acute kidney injury, infection, hypotension, and death."}
{"id": "article-37354_12", "title": "Transcatheter Aortic Valve Replacement -- Complications", "content": "A recent meta-analysis revealed\u00a0statistically significant evidence of lower rates of both acute kidney injury and major bleeding, and a non-statistically significant trend favoring TAVR over SAVR on overall mortality and stroke. Additionally, there was a statistically significant reduction in length\u00a0of stay. To the contrary, TAVR was associated with higher rates of vascular injury, paravalvular regurgitation and the need for permanent pacemaker placement. One caveat, being that high-risk patients in the TAVR cohort of the PARTNER 1-A trial had higher rates of stroke. [9] [10] [11]", "contents": "Transcatheter Aortic Valve Replacement -- Complications. A recent meta-analysis revealed\u00a0statistically significant evidence of lower rates of both acute kidney injury and major bleeding, and a non-statistically significant trend favoring TAVR over SAVR on overall mortality and stroke. Additionally, there was a statistically significant reduction in length\u00a0of stay. To the contrary, TAVR was associated with higher rates of vascular injury, paravalvular regurgitation and the need for permanent pacemaker placement. One caveat, being that high-risk patients in the TAVR cohort of the PARTNER 1-A trial had higher rates of stroke. [9] [10] [11]"}
{"id": "article-37354_13", "title": "Transcatheter Aortic Valve Replacement -- Clinical Significance", "content": "Transcatheter aortic valve replacement is well established in the treatment of severe symptomatic aortic stenosis (AS) for patients considered to be at prohibitive risk for surgery. It is also an alternative to surgical correction in low to intermediate risk patients.", "contents": "Transcatheter Aortic Valve Replacement -- Clinical Significance. Transcatheter aortic valve replacement is well established in the treatment of severe symptomatic aortic stenosis (AS) for patients considered to be at prohibitive risk for surgery. It is also an alternative to surgical correction in low to intermediate risk patients."}
{"id": "article-37354_14", "title": "Transcatheter Aortic Valve Replacement -- Enhancing Healthcare Team Outcomes", "content": "For patients with severe aortic stenosis who are not candidates for open heart surgery, an alternative is transcatheter aortic valve replacement. The procedure is done by an interprofessional team that involves a cardiac surgeon, an interventional cardiologist, anesthesiologist and a radiologist. After the procedure, the patient needs monitoring in a cardiac ICU by critical care nurses. Such an approach may provide the best results with minimal morbidity. TAVR has now been done in thousands of patients in the US and Europe with a procedural success rate of 90%. The 30 day mortality rates have varied from 3-15%. At 2 years, some studies have shown mortality rates of about 35%. Early deaths are usually due to arrhythmias, heart failure and pulmonary complications. It should be emphasized that TAVR is only for patients deemed at high risk for an open procedure. [12] [13] [14] (Level II)", "contents": "Transcatheter Aortic Valve Replacement -- Enhancing Healthcare Team Outcomes. For patients with severe aortic stenosis who are not candidates for open heart surgery, an alternative is transcatheter aortic valve replacement. The procedure is done by an interprofessional team that involves a cardiac surgeon, an interventional cardiologist, anesthesiologist and a radiologist. After the procedure, the patient needs monitoring in a cardiac ICU by critical care nurses. Such an approach may provide the best results with minimal morbidity. TAVR has now been done in thousands of patients in the US and Europe with a procedural success rate of 90%. The 30 day mortality rates have varied from 3-15%. At 2 years, some studies have shown mortality rates of about 35%. Early deaths are usually due to arrhythmias, heart failure and pulmonary complications. It should be emphasized that TAVR is only for patients deemed at high risk for an open procedure. [12] [13] [14] (Level II)"}
{"id": "article-37354_15", "title": "Transcatheter Aortic Valve Replacement -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Transcatheter Aortic Valve Replacement -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}